The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LI.n

Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)

Publications

Paydas S

Management of adverse effects/toxicity of ibrutinib.

Critical reviews in oncology/hematology 2019 Apr;136;56-63 — 2019 Apr — 56-63

Ganatra S, Sharma A, Shah S, Chaudhry GM, Martin DT, Neilan TG, Mahmood SS, Barac A, Groarke JD, Hayek SS, Dani S, Venesy D, Patten R, Nohria A

Ibrutinib-Associated Atrial Fibrillation.

JACC. Clinical electrophysiology 2018 Dec;4;1491-1500 — 2018 Dec — 1491-1500

Kapelios CJ, Bonou MS, Diamantopoulos P, Angelopoulou MK, Masoura C, Barbetseas J, Viniou NA

Ibrutinib-related atrial fibrillation: Therapeutic challenges.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2019 Jul;25;1258-1260 — 2019 Jul — 1258-1260

Moslehi JJ

Cardiovascular Toxic Effects of Targeted Cancer Therapies.

The New England journal of medicine 2016 Oct 13;375;1457-1467 — 2016 Oct 13 — 1457-1467

McMullen JR, Boey EJ, Ooi JY, Seymour JF, Keating MJ, Tam CS

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling.

Blood 2014 Dec 11;124;3829-30 — 2014 Dec 11 — 3829-30

Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Devereux S, Barr PM, Furman RR, Kipps TJ, Cymbalista F, Pocock C, Thornton P, Caligaris-Cappio F, Robak T, Delgado J, Schuster SJ, Montillo M, Schuh A,

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

The New England journal of medicine 2014 Jul 17;371;213-23 — 2014 Jul 17 — 213-23